• Home
  • Ana M Martín-Moreno
Ana M Martín-Moreno

Ana M Martín-Moreno
Indizen technologies · Big Data

Biochemistry and mollecular biology PhD

About

25
Publications
4,603
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,633
Citations
Introduction
Ana M Martín-Moreno currently works at Indizen . Ana does research in Cancer Research, Cell Biology and Neuroscience. Their last research project was 'MicroRNA signatures Hodgkin lymphoma'. During the last years she´s been implicated on the Spanish National Biobank Platform, as a work-line and node coordinator. She´s currently working as programer/consultant in Big Data field. Nowadays the data are growing exponentially even in research field, it´s time for scientist to face the issue and prepare ourshelves and grow with it. Better science comes with better tools and knowleadge.
Additional affiliations
January 2011 - present
MD Anderson Cancer Center Madrid
Position
  • PostDoc Position
September 2006 - December 2010
Cajal Institute
Position
  • Predoctoral Student
Education
September 2012 - September 2013
September 2006 - November 2010
Complutense University of Madrid
Field of study
  • Biochemistry and Molecullar biologie
June 1999 - June 2004
Complutense University of Madrid
Field of study
  • Biologie

Publications

Publications (25)
Article
Full-text available
The International Prognostic Index (IPI) is the most widely used score for non‐Hodgkin lymphoma but lacks the ability to identify a high‐risk population in diffuse large B‐cell lymphoma (DLBCL). Low absolute lymphocyte count and high monocytes have proved to be unfavourable factors. Red‐cell distribution width (RDW) has been associated with inflamm...
Article
Full-text available
Defining the mutational landscape of classic Hodgkin lymphoma is still a major research goal. New targeted next-generation sequencing (NGS) techniques may identify pathogenic mechanisms and new therapeutic opportunities related to this disease. We describe the mutational profile of a series of 57 cHL cases, enriched in Hodgkin and Reed-Sternberg (H...
Article
Full-text available
The study included 1848 diffuse large B-cell lymphoma (DLBCL)patients treated with chemotherapy/rituximab. The aims were to validate the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) and explore the effect of adding high Beta-2 microglobulin (β2M), primary extranodal presentation and intense treatment to the NCCN-I...
Article
Full-text available
There is evidence of altered vascular function, including cerebrovascular, in Alzheimer's disease (AD) and transgenic models of the disease. Indeed vasoconstrictor responses are increased, while vasodilation is reduced in both conditions. β-Amyloid (Aβ) appears to be responsible, at least in part, of alterations in vascular function. Cannabinoids,...
Article
Full-text available
Cannabinoid CB2 receptors (CB2Rs) are emerging as important therapeutic targets in brain disorders that typically involve neurometabolic alterations. We here addressed the possible role of CB2Rs in the regulation of glucose uptake in the mouse brain. To that aim, we have undertaken 1) measurement of 3H-deoxyglucose uptake in cultured cortical astro...
Article
Classical Hodgkin´s lymphoma (cHL) is a clonal proliferation of the characteristic Hodgkin and Reed Sternberg cells (HRS), diluted in a reactive inflammatory background, and characterized by a defective B cell immunophenotype. Few studies have been aimed to the identification of the driver mutations in this disease, and only occasional gene mutatio...
Article
Full-text available
Tumour-associated macrophages (TAMs) have been associated with survival in classic Hodgkin lymphoma (cHL) and other lymphoma types. The maturation and differentiation of tissue macrophages depends upon interactions between colony-stimulating factor 1 receptor (CSF1R) and its ligands. There remains, however, a lack of consistent information on CSF1R...
Article
Full-text available
There is growing evidence that leptin is able to ameliorate Alzheimer's disease (AD)-like pathologies, including brain amyloid-β (Aβ) burden. In order to improve the therapeutic potential for AD, we generated a lentivirus vector expressing leptin protein in a self-inactivating HIV-1 vector (HIV-leptin), and delivered this by intra-cerebroventricula...
Article
Although specific microRNA (miRNA) signatures in classical Hodgkin lymphoma (cHL) have been proposed, their relationship with clinical outcome remains unclear. Despite treatment advances, a substantial subset of patients with advanced cHL are refractory to standard therapies based on adriamycin and its variants. Global miRNA expression data of 29 a...
Article
Full-text available
A subset of patients with advanced classical Hodgkin's lymphoma is refractory to standard therapies. Therefore, it is relevant to identify new biologically-based prognostic markers. Recently, tumor associated macrophages have been proposed as a factor that predicts survival, although contradictory results have also been reported. Here we analyzed f...
Article
Full-text available
Alzheimer's disease (AD) brain shows an ongoing inflammatory condition and non-steroidal anti-inflammatories diminish the risk of suffering the neurologic disease. Cannabinoids are neuroprotective and anti-inflammatory agents with therapeutic potential. We have studied the effects of prolonged oral administration of transgenic amyloid precursor pro...
Data
Co-localization of CB2 and Iba-1 inmmunostaining in quinolinic acid injected striatum. Iba-1 positive microglia in striatum also express CB2 receptor protein ipsilateral to the toxin injection, but was absent in the contralateral (unlesioned) striatum. Tg APP microglial cells are devoid of CB2 immunostaining.
Data
Additional methods. (quinolinic acid striatal lesion and blockade of CB2 antibodies with CB2 blocking peptide) and additional file 1, which includes the antibodies, commercial source and dilution, used in immunohistochemistry and Western blotting.
Data
Full-text available
Blockade of CB2 antibodies 744 and 746 with CB2 antigenic peptide. The CB2 peptide completely blocked immunostaining.
Article
Full-text available
Retrograde messengers adjust the precise timing of neurotransmitter release from the presynapse, thus modulating synaptic efficacy and neuronal activity. 2-Arachidonoyl glycerol, an endocannabinoid, is one such messenger produced in the postsynapse that inhibits neurotransmitter release upon activating presynaptic CB(1) cannabinoid receptors. Cogni...
Article
Full-text available
Microglial activation is an invariant feature of Alzheimer's disease (AD). It is noteworthy that cannabinoids are neuroprotective by preventing β-amyloid (Aβ)-induced microglial activation both in vitro and in vivo. On the other hand, the phytocannabinoid cannabidiol (CBD) has shown anti-inflammatory properties in different paradigms. In the presen...
Article
Neural injury leads to inflammation and activation of microglia that in turn may participate in progression of neurodegeneration. The mechanisms involved in changing microglial activity from beneficial to chronic detrimental neuroinflammation are not known but reactive oxygen species (ROS) may be involved. We have addressed this question in Nrf2-kn...
Article
Full-text available
El papel neuroprotector de los cannabinoides in vivo e in vitro es conocido, pero el mecanismo a través del cual llevan a cabo su acción neuroprotectora, en el contexto de la enfermedad de Alzheimer, no había sido abordado en su conjunto. Los objetivos del presente trabajo son 5: 1. Estudiar el efecto de distintos agonistas cannabinoides, en partic...

Network

Cited By